Entity

Time filter

Source Type

San Diego, CA, United States

The invention relates to compositions and methods for gene expression analysis. In some embodiments, the invention provides compositions and methods for amplifying targets in a degraded nucleic acid sample. In some embodiments, the invention provides methods for determining the quality of nucleic acids (e.g., the degree of degradation) in a nucleic acid sample. The invention also provides methods for producing a gene expression profile from a degraded RNA sample.


News Article | December 24, 2014
Site: www.xconomy.com

San Diego-based AltheaDx, which uses diagnostic tests and bioinformatics to help doctors identify the optimal drugs based on a patient’s genetic make-up, plans to raise as much as $69 million in an IPO. The company, which began operating in 2008, says in its IPO filing that it has used its IDgenetix technology to complete tests on more than 13,500 patient samples through the first nine months of the year. More than half of those were done in the third quarter. AltheaDx has financed its operations primarily through private equity deals, debt, and by generating revenue from its R&D services to numerous biopharmaceutical partners, primarily in cancer diagnostics. The company generated about $13.6 million in revenue through the first nine months of 2014, and has about $7.5 million in available cash. However, AltheaDx says it also has incurred significant operating losses since inception. At the end of September, it had an accumulated deficit of $19.2 million, and had borrowed $12.4 million against a $20 million credit facility held by Silicon Valley Bank. According to the filing, IDgenetix assesses the genes involved in both the metabolism and pharmacological effect of numerous drugs. The company currently offers 13 tests for cardiovascular disease, neuropsychiatric disorders, and pain. Additional tests are under development in neurology and rheumatology. The company offers its commercial IDgenetix services to multiple healthcare providers, and says reimbursement for its testing services comes from third-party payers, including Medicare and Medicaid, private health insurance plans, hospitals, and managed care organizations, as well as individual patients. Medicare patients accounted for 59 percent of all IDgenetix tests done through the first nine months of the year. AltheaDx says its technology addresses the current “trial and error” process that doctors use to find the particular drug that works best for each patient. The diagnostic test identifies key metabolic enzymes and other applicable biological drug targets that vary among individuals. The company says its bioinformatics technology also screens for unfavorable metabolic interactions that can arise when multiple drugs are prescribed for the same patient.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vx3f8n/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 - Global Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. 10. The Future of the Clinical Laboratory


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2jd9w8/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - Asia Pacific Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ws2hdw/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - North American Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. 7. The Future of the Clinical Laboratory

Discover hidden collaborations